SWOG clinical trial number
CTSU/E1Z11

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Closed
Phase
Abbreviated Title
AIMSS
Status Notes
Permanent Closure – Effective 10/22/18
Activated
06/15/2013
Closed
10/22/2018
Participants
CTSU

Research committees

Symptom Management and Survivorship
Breast Cancer

Treatment

Anastrozole

Publication Information Expand/Collapse

2024

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11

V Stearns;O Jegede;V Chang;T Skaar;J Berenberg;R Nand;A Shafqat;N Jacobs;W Luginbuhl;P Gilman;A Benson;J Goodman;G Buchschacher;NL Henry;C Loprinzi;P Flynn;E Mitchell;M Fisch;J Sparano;L Wagner Clinical Cancer Research Jul 1;30(13):2709-2718

PMid: PMID38640040 | PMC number: PMC11287923

2021

Prospective Validation of Genetic Predictors of Aromatase Inhibitor-Associated Musculoskeletal Symptoms (AIMSS) in a Racially Diverse Cohort: Results from ECOG-ACRIN E1Z11

V Stearns;O Jegede;V Chang;T Skaar;J Berenberg;R Nand;A Lyss;N Jacobs;W Luginbuhl;P Gilman;A Benson;J Goodman;G Buchschacher;NL Henry;C Loprinzi;P Flynn;E Mitchell;MJ Fisch;J Sparano;L Wagner J Clin Oncol 39, 2021 (suppl 15; abstr 12003) (American Society of Clinical Oncology Annual Meeting 2021, oral)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU-A012303

Shortstop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer who Achieve PCR After Neoadjuvant Chemotherapy with HER2 Blockade
Research Committee(s)
Breast Cancer
Activated
07/25/2025
Open
SWOG Clinical Trial Number
CTSU-A012301

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Management and Survivorship
Activated
10/30/2023
Accrual
32%
Open
Phase